Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2021 (FY2020)

from the beginning

Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2021 (FY2020)

• Safe Harbor for Forward‐Looking Statements and Use of Document

• Highest‐ever Quarterly Revenue and Adjusted Operating Profit

• Adjusted Operating Profit Variance Analysis

• Revenue by Region

• Revenue by Business Segment

• Cardiac and Vascular : Progressing Recovery in the Number of Procedures

• General : Exceeded the Impact of Decreased Demand by Solid Hospital Sales of Alliance and Infection Control Products

• Blood and Cell Technologies : Continuous Increase in Both Revenue and Profit

• Key Assumptions of FY20 Q4 Projection

• Revision of FY20 Guidance

• Major Topics in FY20 Q3

• FY20 New Product Pipeline

Reference

• FY20 Q3YTD Revenue and Growth by Region

• Operating Expenses

• Quarterly Results

• Adjusted Operating Profit : Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows

• Foreign Exchange Sensitivity

• The Status of Convertible Bonds

@